Clinical trials: MSA
Lymphoma
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving…
- Trial name
- NCT00450801
- Testing
- Rituximab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Multiple System Atrophy, MSA - Multiple System Atrophy
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
- Trial name
- NCT05698017
- Testing
- hOMSC300
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Cytora Ltd.
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
CNS Lymphoma
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy
- Trial name
- NCT01083342
- Testing
- MTX, MVD, VIA
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Polycystic Ovary Syndrome (PCOS), Metabolic Syndrome
Malay Women With PCOS and Their Association With Metabolic Syndrome
The abnormalities that characterize the Metabolic Syndrome (MetS) confer an increased risk of cardiovascular and other diseases.
- Trial name
- MPMSS (NCT03414957)
- Testing
- Hormonal and biochemical blood tests and ultrasound scanning
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cyberjaya University College of Medical Sciences
Multiple System Atrophy
Natural History and Disease Progression Biomarkers of Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction.
- Trial name
- ASPIRE-MSA (NCT04229173)
- Testing
- MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional)
- Where
- 10 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Type 2 Diabetes Mellitus
Dietary Intervention in Diabetes Mellitus (DIDM)- Intermediate and Acute Effects
Lifestyle modification, in particular adopting an appropriate dietary pattern, is generally accepted as the cornerstone for the treatment of people with type 2 diabetes mellitus (T2DM).
- Trial name
- DIDM (NCT01585818)
- Testing
- Low Glycemic Index (LGI) intervention arm, Standard Diet Intervention
- Where
- Singapore
- Volunteers
- 160 people
- Sponsor
- National University Hospital, Singapore
Multiple System Atrophy, MSA
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
- Trial name
- NCT02388295
- Testing
- AZD3241
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Vitamin D Deficiency
Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics
Much research on vitamin D status has focused on seasonal variations in serum 25(OH)D levels in populations living at high altitudes and those of light-skinned Caucasian extraction, with little work done in multi ethnic…
- Trial name
- NCT02389179
- Testing
- Vitamin D3
- Where
- Malaysia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sharifah Faradila bt Wan Muhamad Hatta
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Multiple system atrophy (MSA) is a disorder of the nervous system of unclear cause. In MSA there is degeneration (progressive loss) of nerve cells in several brain and spinal cord regions.
- Trial name
- NCT02035761
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Multiple System Atrophy
Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that leads to major disability, forcing patients and caregivers to adapt their environment and lifestyle.
- Trial name
- ETP@MS (NCT05819957)
- Testing
- Therapeutic Education Program (TEP)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
MSA
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by [F-18]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9…
- Trial name
- NCT03033680
- Testing
- [F-18]PBR06
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Pulmonary Disease, Chronic Obstructive
COPD MSA 3 Regions: Epidemiology and Risk Factors of COPD in Rural Environment (BM3R)
The agricultural environment presents a unique profile in terms of epidemiology of pulmonary diseases. Certainly due to persistent exposure to organic particles, the prevalence of COPD is higher in farmers than in the general…
- Trial name
- BM3R (NCT03299907)
- Testing
- Spirometry
- Volunteers
- 5,263 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
- Trial name
- NCT07289477
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes(MDS)
Collection of Samples From Patients With MDS
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
- Trial name
- NCT03072498
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- PersImmune, Inc